NASDAQ:KROS

Keros Therapeutics (KROS) Stock Forecast, Price & News

$30.82

-1.06 (-3.32%)

(As of 10/2/2023 ET)

Compare

Today's Range: $30.57
▼
$33.08
50-Day Range: $31.57
▼
$43.01
52-Week Range: $30.57
▼
$59.96

Volume: 294,439 shs
Average Volume: 209,583 shs
Market Capitalization: $914.12 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $94.33

Keros Therapeutics MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 206.1% Upside
$94.33 Price Target
Short Interest: Bearish
5.60% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.84
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($5.25) to ($5.22) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.15 out of 5 stars

Medical Sector

484th out of 969 stocks

Pharmaceutical Preparations Industry

223rd out of 452 stocks

3.5

Analyst's Opinion

Consensus Rating
Keros Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $94.33, Keros Therapeutics has a forecasted upside of 206.1% from its current price of $30.82.
Amount of Analyst Coverage
Keros Therapeutics has only been the subject of 3 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
5.60% of the float of Keros Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Keros Therapeutics has a short interest ratio ("days to cover") of 6.8.
Change versus previous month
Short interest in Keros Therapeutics has recently increased by 3.51%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Keros Therapeutics does not currently pay a dividend.
Dividend Growth
Keros Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for KROS.

3.2

News and Social Media Coverage

News Sentiment
Keros Therapeutics has a news sentiment score of 1.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Keros Therapeutics this week, compared to 1 article on an average week.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Keros Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
28.00% of the stock of Keros Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
75.56% of the stock of Keros Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Keros Therapeutics are expected to grow in the coming year, from ($5.25) to ($5.22) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Keros Therapeutics is -6.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Keros Therapeutics is -6.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Keros Therapeutics has a P/B Ratio of 3.06. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Keros Therapeutics (NASDAQ:KROS) Stock

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical need in the United States. The company's lead protein therapeutic product candidate KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-047, a small molecule product candidate that is in Phase II clinical trials for the treatment of functional iron deficiency; and KER-012, which is in Phase II clinical trials to treat pulmonary arterial hypertension and cardiovascular disorders. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

KROS Price History

30 days | 90 days | 365 days | Advanced Chart

KROS Stock News Headlines

August 31, 2023 | markets.businessinsider.com

Wedbush Sticks to Their Buy Rating for Keros Therapeutics (KROS)

August 20, 2023 | nasdaq.com

Benjamin Graham Detailed Fundamental Analysis - KROS

October 2, 2023 | Behind the Markets (Ad)

[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software"

The Washington Post Reports it's: "A revolution in warfare." The Sunday Times Reports it's: "a revolutionary power." Early investors can reap 5,633% gains as England, Germany, Japan and Australia rush to sign contracts. Get the name of the stock here >>>

August 9, 2023 | markets.businessinsider.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Cigna (CI), Keros Therapeutics (KROS) and Qiagen (QGEN)

August 9, 2023 | markets.businessinsider.com

Truist Financial Remains a Buy on Keros Therapeutics (KROS)

August 8, 2023 | msn.com

Wedbush Reiterates Keros Therapeutics (KROS) Outperform Recommendation

August 8, 2023 | finanznachrichten.de

Keros Therapeutics, Inc.: Keros Therapeutics Reports Recent Business Highlights and Second Quarter 2023 Financial Results

August 8, 2023 | markets.businessinsider.com

Wedbush Sticks to Its Buy Rating for Keros Therapeutics (KROS)

October 2, 2023 | Behind the Markets (Ad)

[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software"

August 7, 2023 | finance.yahoo.com

Keros Therapeutics Reports Recent Business Highlights and Second Quarter 2023 Financial Results

August 2, 2023 | seekingalpha.com

Keros Therapeutics: Hematological Therapies Continue To Advance

July 31, 2023 | markets.businessinsider.com

Wedbush Initiates a Buy Rating on Keros Therapeutics (KROS)

July 27, 2023 | finance.yahoo.com

Corrected: Keros Therapeutics to Host Conference Call and Webcast to Provide an Overview of TROPOS, the KER-012 Phase 2 Clinical Trial in Patients with Pulmonary Arterial Hypertension

July 26, 2023 | markets.businessinsider.com

Where Keros Therapeutics Stands With Analysts

July 24, 2023 | finance.yahoo.com

Keros Therapeutics to Host Conference Call and Webcast to Provide an Overview of TROPOS, the KER-012 Phase 2 Clinical Trial in Patients with Pulmonary Arterial Hypertension

July 23, 2023 | fool.com

Keros Therapeutics (NASDAQ: KROS)

June 12, 2023 | finance.yahoo.com

Keros Therapeutics Announces Update to Participation at the Goldman Sachs 44th Annual Global Healthcare Conference

June 9, 2023 | markets.businessinsider.com

H.C. Wainwright Remains a Buy on Keros Therapeutics (KROS)

June 9, 2023 | finance.yahoo.com

Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its KER-050 Program and Preclinical Data from its ALK2 Inhibitor Program at the 28th Annual Congress of the European Hematology Association

June 7, 2023 | finance.yahoo.com

Keros Therapeutics to Present at Goldman Sach’s 44th Annual Global Healthcare Conference

May 29, 2023 | markets.businessinsider.com

Keros Therapeutics (KROS) Receives a Rating Update from a Top Analyst

May 23, 2023 | markets.businessinsider.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Rain Therapeutics (RAIN) and Keros Therapeutics (KROS)

May 22, 2023 | finance.yahoo.com

Keros Therapeutics Presents Preclinical and Clinical Data from its KER-012 Program at the American Thoracic Society International Conference

May 11, 2023 | finance.yahoo.com

Keros Therapeutics to Present at the 28th Annual Congress of the European Hematology Association

May 9, 2023 | msn.com

HC Wainwright & Co. Reiterates Keros Therapeutics (KROS) Buy Recommendation

May 8, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Karuna Therapeutics (KRTX) and Keros Therapeutics (KROS)

May 7, 2023 | seekingalpha.com

Keros Therapeutics GAAP EPS of -$1.26

See More Headlines

Receive KROS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Keros Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

KROS Company Calendar

Last Earnings: 8/07/2023
Today: 10/02/2023
Next Earnings (Estimated): 11/02/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:KROS
CUSIP: N/A
CIK: 1664710
Web: www.kerostx.com
Phone: 617-314-6297
Fax: N/A
Employees: 121
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $94.33
High Stock Price Forecast: $110.00
Low Stock Price Forecast: $65.00
Forecasted Upside/Downside: +206.1%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($4.54)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-104,680,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -42.19%
Return on Assets: -38.93%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 20.77
Quick Ratio: 20.77

Sales & Book Value

Annual Sales: $20.10 million
Price / Sales: 45.48
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $10.07 per share
Price / Book: 3.06

Miscellaneous

Outstanding Shares: 29,660,000
Free Float: 21,357,000
Market Cap: $914.12 million
Optionable: Not Optionable
Beta: 1.16

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

Dr. Jasbir S. Seehra Ph.D. (Age 67)
Pres, CEO, Treasurer, & Director
Comp: $985.58k

Mr. Christopher Rovaldi M.Sc. (Age 49)
Chief Operating Officer
Comp: $708.75k

Dr. Simon Cooper MBBS (Age 53)
Chief Medical Officer
Comp: $654.27k

Mr. Keith C. Regnante MBA (Age 53)
Chief Financial Officer

Ms. Esther Cho J.D.
Sr. VP, Gen. Counsel & Sec.

Ms. Robin Wagner
VP of HR

Dr. Jennifer Lachey Ph.D. (Age 50)
Sr. VP of Discovery

Mr. John Oram M.B.A.
Sr. VP of Program & Portfolio Management

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

KROS Stock - Frequently Asked Questions

Should I buy or sell Keros Therapeutics stock right now?: 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Keros Therapeutics in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" KROS shares.
View KROS analyst ratings or view top-rated stocks.
What is Keros Therapeutics' stock price forecast for 2023?: 7 Wall Street analysts have issued 1 year target prices for Keros Therapeutics' stock. Their KROS share price forecasts range from $65.00 to $110.00. On average, they expect the company's share price to reach $94.33 in the next year. This suggests a possible upside of 206.1% from the stock's current price.
View analysts price targets for KROS or view top-rated stocks among Wall Street analysts.
How have KROS shares performed in 2023?: Keros Therapeutics' stock was trading at $48.02 on January 1st, 2023. Since then, KROS stock has decreased by 35.8% and is now trading at $30.82.
View the best growth stocks for 2023 here.
When is Keros Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our KROS earnings forecast.
How were Keros Therapeutics' earnings last quarter?: Keros Therapeutics, Inc. (NASDAQ:KROS) announced its earnings results on Monday, August, 7th. The company reported ($1.27) EPS for the quarter, beating analysts' consensus estimates of ($1.34) by $0.07. During the same quarter in the prior year, the business posted ($1.13) earnings per share.
What ETFs hold Keros Therapeutics' stock?: ETFs with the largest weight of Keros Therapeutics (NASDAQ:KROS) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC) and ALPS Medical Breakthroughs ETF (SBIO).BNY Mellon Innovators ETF (BKIV).

What other stocks do shareholders of Keros Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Keros Therapeutics investors own include AbbVie (ABBV), Brainstorm Cell Therapeutics (BCLI), Cloudera (CLDR), CVS Health (CVS), Inovio Pharmaceuticals (INO), Iovance Biotherapeutics (IOVA), Karyopharm Therapeutics (KPTI), Neurocrine Biosciences (NBIX), Novavax (NVAX) and Pfizer (PFE).
When did Keros Therapeutics IPO?: (KROS) raised $75 million in an initial public offering (IPO) on Wednesday, April 8th 2020. The company issued 5,000,000 shares at $14.00-$16.00 per share. Jefferies, SVB Leerink and Piper Sandler acted as the underwriters for the IPO and H.C. Wainwright & Co. was co-manager.
What is Keros Therapeutics' stock symbol?: Keros Therapeutics trades on the NASDAQ under the ticker symbol "KROS."
How do I buy shares of Keros Therapeutics?: Shares of KROS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Keros Therapeutics' stock price today?: One share of KROS stock can currently be purchased for approximately $30.82.
How much money does Keros Therapeutics make?: Keros Therapeutics (NASDAQ:KROS) has a market capitalization of $914.12 million and generates $20.10 million in revenue each year. The company earns $-104,680,000.00 in net income (profit) each year or ($4.54) on an earnings per share basis.
How many employees does Keros Therapeutics have?: The company employs 121 workers across the globe.
How can I contact Keros Therapeutics?: Keros Therapeutics' mailing address is 99 HAYDEN AVENUE SUITE 120 (BLD E) LEDGEMONT TECHNOLOGY CENTER, LEXINGTON MA, 02421. The official website for the company is www.kerostx.com. The company can be reached via phone at 617-314-6297 or via email at jbalanova@troutgroup.com.

This page (NASDAQ:KROS) was last updated on 10/2/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial